Restrictive Lung Disease Flashcards

1
Q

What is restrictive lung disease?

A
  • Espansion of the lung is restricted by:
    a) Intrinsic lung disease:
  • alterations to lung parenchyma [interstitial lung disease (ILD)]
    b) Extrinsic disorders:
  • compress lungs or limit expansion:
    1. Pleural
    2. Chest wall
    3. Neuromuscular (decrease ability of respiratory muscles to inflate / deflate the lungs)
    [Lung volumes are small in restrictive lung disease]
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is meant by lung parenchyma? What are it’s cellular components?

A

“the alveolar regions of the lung”

CELLULAR COMPONENTS:

  1. Alveolar type 1 epithelial cell – gas exchange surface (approx. 70m2) [LINE ALVEOLAR REGION, THIN]
  2. Alveolar type 2 epithelial cell – surfactant to reduce surface tension, stem cell for repair [PREVENTS ALVEOLAR COLLAPSE]
  3. Fibroblasts – produce extracellular matrix (ECM) e.g Collagen type 1 [STRUCTURAL INTEGRITY & SIGNALLING]
  4. Alveolar macrophages – phagocytose foreign material, surfactant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is Interstitial lung disease? What are the different types of ILD’s

A

“Inflammation or fibrosis in the interstitial space- space b/t alveolar epithelium and capillary epithelium”

  1. Idiopathic (a disease of unknown cause)
  2. Autoimmune related
  3. Exposure related
  4. With cysts or airspace filling
  5. Sarcoidosis
  6. Others (e.g. Eosiniophilic pneumonia)

(different types of restrictive lung diseases vary in prognosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What clinical presentations would you find in the history of Interstitial lung diseases?

A
  1. Progressive breathlessness
  2. Non-productive cough (dry)
  3. Limitation in exercise tolerance
  4. Symptoms of connective tissue disease (e.g, joint issues, rash, dry eyes/ mouth, etc)
  5. Occupational and exposure history (not just their current job)
  6. Medication history (drug induced ILD, http://www.pneumotox.com)
  7. Family history (up to 20% of idiopathic ILDs are familial)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What clinical presentations would you find in Interstitial lung diseases?

A
  1. Low oxygen saturations (resting or exertion) [Scarring of gas exchange surface]
  2. Fine bilateral inspiratory crackles
  3. Digital clubbing [swollen fingers and nails]

(+/- features of connective tissue disease – skin, joints, muscles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the investigations in ILD?

A
  • Blood tests e.g. anti-nuclear antibody (ANA), rheumatoid factor (RhF) [INDICATES RHEUMATOID A], anti-citrullinated peptide (CCP)
  • Pulmonary function tests
  • 6-minute walk test (6MWT) [see how far you can walk before complete oxygen saturation] – SpO2 ≤ 88% associated with increased risk of death
  • High-resolution CT scan (HRCT) = pattern of disease

Invasive testing:
* Bronchoalveolar lavage (BAL) [flood lungs with saline & suck as much as possible out & study the sample under a microscope]
* Surgical lung biopsy (2-4% mortality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the lung pysiology in ILD

A
  1. Scarring makes the lung stiff - ↓ lung compliance
  2. ↓ Lung volumes (TLC, FRC, RV)
  3. ↓ FVC (forced vital capacity- indicates how bad the ILD is)
  4. ↓ diffusing capacity of lung for carbon monoxide (DLCO)
  5. ↓ arterial PO2 – particularly with exercise
  6. Normal or ↑ FEV1/ FVC ratio
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How would you use a High-resolution CT (HRCT) – for ILD diagnosis

A
  • CT uses X-rays to obtain cross-sectional images
  • Rotating X-ray source and detectors spin around the patient gathering data
  • HRCT - thin slices and high-frequency reconstruction – gives good resolution at level of secondary pulmonary lobule (smallest functional lung unit identifiable on CT)
  1. High - density substances e.g. bone/ muscles absorb more x-rays and appear whiter
    DENSE WHITE PATCHES CAN INDICATE PNEUMONIA AND ILD’s
  2. Low - density substances e.g. air absorb few x-rays and appear darker
  • Images viewed in axial, sagittal and coronal view
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How would you manage the early stages of Interstitial lung disease ?

A
  1. Pharmacological therapy – immunosuppressive drugs (not suitable for every type of scarring), antifibrotics (prevent scarring)
  2. Clinical trials
  3. Patient education
  4. Vaccination
  5. Smoking cessation
  6. Treatment of co-morbidities – gastroesophageal reflux, obstructive sleep apnoea, pulmonary hypertension
  7. Pulmonary rehabilitation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How would you manage the late stages of Interstitial lung disease ?

A
  1. Supplemental oxygen
  2. Lung transplantation
  3. Palliative care – symptom management, end-of-life care
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is idiopathic pulmonary fibrosis (IPF)?

A

“Progressive, scarring lung disease of unknown cause” (no cure currently- treatment attempts to slow it down)
- Incidence increases with age - most >60yrs
- More common in men
- Average decline in forced vital capacity (FVC) = 150 – 200mls / year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are some features of the trajectory of idiopathic pulmonary fibrosis?

A
  1. Disease is progressive- patients can go through exacerbations
  2. Acute exacerbations of IPF (AE-IPF)
    - Occur in 5-15% of patients
    - Median survival 3-4 months
    - In-hospital mortality ~50%
  3. Patients never recover to original baseline after each exacerbation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the mechanism of idiopathic pulmonary fibrosis

A
  1. Either:
    -Genetic susceptibility (MUC5B, DSP)
    -Environmental triggers (smoke, viruses, pollutants, dusts)
    - Cellular ageing
    cause injury to alveolar epithelium
  2. Fibroblasts are recruited= aberrant fibroblast activity
  3. Leads to excess accumulation of ECM= scarring
  4. Leads to remodelling & honeycomb cyst formation (makes the lungs less efficient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the Histopathology of IPF (idiopathic pulmonary fibrosis)

A
  • Microscopic honeycomb cysts
  • Airspaces replaced by scar tissue
  • Fibroblastic foci= proliferating fibroblasts/ myofibroblasts (it is an active disease)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are the characteristic features of IPF (idiopathic pulmonary fibrosis) on CT scan?

A
  • Lungs shrink
  • Subpleural honeycombing
  • Traction bronchiectasis (airways ‘tugged apart’ by scar tissue in lungs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What affect does immunosuppression have on idiopathic pulmonary fibrosis?

A

Immunosuppression is harmful in IPF

PANTHER-IPF trial (Randomized, double-blind, placebo-controlled trial)
- Combination treatment with steroids + immunosuppressants given to subjects
- increased risk of death and hospitalisation
- Led to a change in the conventional treatment for IPF

17
Q

How is idiopathic pulmonary fibrosis treated?

A

Antifibrotics (slow disease progression in IPF but do not cure)
- Drugs target fibrotic pathways (e.g. Galectin- 3 inhibitor, Anti-IL-13)

18
Q

What is hypersensitivity pneumonitis (HP)?

A

ILD caused by immune- mediated response in susceptible and sensitised individuals to inhaled environmental antigens
(Involves small airways and parenchyma)

19
Q

How can you classify hypersentivity pneumonitis?

A

a) Acute HP - Intermittent, high-level exposure – abrupt symptom onset, flu-like syndrome 4-12 hrs after exposure

b) Chronic HP - Long-term, low-level exposure
* Nonfibrotic (purely inflammatory)
* Fibrotic – associated with higher mortality

20
Q

Describe the mechanism for hypersensitivity pneumonitis

A
  1. Antigen exposure and processing by the innate immune system
  2. Inflammatory response mediated by T-helper cells and antigen-specific immunoglobulin (Ig) G antibodies
  3. Accumulation of lymphocytes and formation of granulomas (switch from innate inflammatory response to adaptive)- possibly triggered by second hit? e.g. viral infection
21
Q

What are some example of environmental antigens that could trigger HP?

A
  • Moldy hay and straw
  • Parrots
  • Wind instruments (poorly cleaned)
  • Outdoor hot tubs
  • birds
  • rats
22
Q

How would you attempt to diagnose HP?

A
  1. Detailed exposure history – antigen not identified in ~50%
  2. Inspiratory ‘squeaks’ on auscultation - caused by the coexisting bronchiolitis
  3. Specific circulating IgG antibodies (serum precipitins) to potential antigens [indicates exposure not disease]
  4. HRCT
  5. Bronchoalveolar lavage (BAL) lymphocyte count >30%
23
Q

How would you treat HP?

A
  1. Complete antigen removal / avoidance is crucial
  2. Corticosteroids often used
  3. Immunosuppressants e.g. mycophenolate mofetil (MMF) and azathioprine used but poor evidence base
  4. Progressive, fibrotic HP – Nintedanib (antifibrotic)
24
Q

What is Systemic sclerosis (SSc) ?

A

“SSc is an autoimmune connective tissue disease characterised by immune dysregulation and progressive fibrosis that affects skin, with variable internal organ involvement”
- Affects young, middle-aged women
- Slow indolent course vs. rapid progression
- Male, older age, smoker, >20% extent on HRCT, FVC <70% =worse survival

25
Q

What are clinical features of systemic sclerosis?

A
  1. Sclerodactyly (thickening/ tightening of skin on the fingers)
  2. Abnormal nailfold capillaroscopy
  3. Digital ulcer (ulcers on the nails)
  4. Raynaud’s (causes some areas of the body — such as fingers and toes — to feel numb from reduced blood circulation)
  5. Telangiectasias (small, widened blood vessels on the skin, e.g. on the face)
26
Q

How can you classify SSc?

A

Can be classified based on skin involvement -
a) limited cutaneous SSc
(Pulmonary hypertension more common)
b) diffuse cutaneous SSc
(ILD more common)

27
Q

What autoantibodies cause SSc?

A
  1. Anti-centromere
  2. Anti-Scl-70 - associated with increased with ILD
28
Q

Describe the pathogenesis of SSc-ILD

A
  1. Autoantibodies=
  2. Tissue injury (genetic predisposition, oxidative stress, environmental stimuli, etc)
  3. Vascular injury (tissue hypoxia & ineffective angiogenesis)
  4. Autoimmunity also leads to release of IL-6= Fibrocytes recuirted & fibroblasts are activated
  5. Myofibroblasts express aSMA and produce collagen
    =Sclerosis (hardening of tissue)
29
Q

What are the HRCT patterns in SSc-ILD?

A

HRCT (high resolution CT scan)
Non-specific interstitial pneumonia (NSIP) pattern is the most common pattern

30
Q

How would you manage SSc?

A
  1. Determined by disease extent on HRCT and lung function trajectory (monitor every 3 – 6 months)
  2. Corticosteroid use is controversial and risk of renal crisis with high doses (>10mg/day)
  3. Immunosuppressives – cyclophosphamide, mycophenolate mofetil (MMF)1
  4. Progressive fibrotic phenotype– Nintedanib (antifibrotic)